Melissa Grier, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 2 carriers
- Office
- 1
Offices
1 location · Obhg California PC · 94 clinicians in this group
Looking this up.
Hospitals listed: Huntington Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Grier’s office at (408) 378-6131 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A82969 · Current
Licensed to practise in California · since 2003 · expires 2026-10-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Huntington HospitalPasadena, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for Huntington Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 6 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.68 (0 to 1.56) · 2,225 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 149.43 (106.58 to 192.28) · 128 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 67 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.8 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 475 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.7 · 822 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 463 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,850 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.36) · 10,123 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 10,515 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.4 (2.67 to 6.13) · 2,613 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.32 (0 to 2.86) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.44 to 4.11) · 2,457 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.71 (1.95 to 13.48) · 1,211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.8 to 7.36) · 1,189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.85 (0.42 to 3.29) · 825 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0.03 to 1.09) · 8,956 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 269 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.448 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.977 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.423 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 253 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.9 · 846 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.2 · 176 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.1 · 542 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 9.5 · 864 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 1,144 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.2 to 8.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (6.9 to 15.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 260 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.1 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 201 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.8 to 15.8) · 365 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 786 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,430 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$3,968
Medicare paid this office $3,968 for 26 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 16 | $2,208 | $100 |
Who their Medicare patients are
26 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.89. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 54%.
The office billed $9,636, Medicare allowed $5,875 and paid $3,968; for 41 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 26 | 41 | 73 | 0.89 | $9,636 | $3,968 |
| 2023 | 46 | 90 | 71 | 0.92 | $20,443 | $8,933 |
| 2022 | 41 | 81 | 69 | 0.92 | $22,402 | $9,593 |
| 2021 | 23 | 55 | 67 | 0.85 | $10,603 | $5,229 |
| 2020 | 17 | 45 | 62 | 0.62 | $10,109 | $3,415 |
| 2019 | 28 | 53 | 64 | 1.07 | $13,335 | $5,757 |
| 2013 | 15 | 31 | 67 | 1.11 | $9,940 | $3,398 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 32 | $3,968 | $94 |
| Short return visit (20+ min) | 13 | $1,010 | $59 |
2022: 2 services
| Return visit (30+ min) | 24 | $3,392 | $103 |
| New patient visit (45+ min) | 12 | $1,745 | $145 |
2021: 1 service
| Return visit (30+ min) | 17 | $2,934 | $95 |
2020: 1 service
| Return visit (30+ min) | 11 | $1,410 | $74 |
2019: 1 service
| Return visit (30+ min) | 16 | $2,371 | $95 |
Medicaid work
$767 in 2023
Medicaid paid $767 for 21 billed services this clinician did in 2023, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EMERGENCY DEPT VISIT LOW MDM | 21 | $767 |
| 2023 | 21 | 1 | 18 | $767 |
| 2022 | 57 | 1 | 24 | $1,690 |
| 2021 | 93 | 2 | 20 | $3,204 |
| 2020 | 216 | 6 | 32 | $3,859 |
| 2019 | 778 | 6 | 52 | $20,867 |
| 2018 | 1,474 | 11 | 82 | $69,708 |
See the largest Medicaid services in earlier years
2022
| EMERGENCY DEPT VISIT LOW MDM | 57 | $1,690 |
2021
| EMERGENCY DEPT VISIT LOW MDM | 77 | $2,660 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 16 | $544 |
2020
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 35 | $1,107 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 25 | $935 |
| FETAL NON-STRESS TEST | 112 | $697 |
| Service | 14 | $627 |
| EMERGENCY DEPT VISIT LOW MDM | 13 | $437 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 17 | $56 |
2019
| Service | 276 | $9,378 |
| Service | 75 | $5,205 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 94 | $2,688 |
| FETAL NON-STRESS TEST | 257 | $1,760 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 53 | $1,118 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 23 | $718 |
2018
| Service | 366 | $25,400 |
| Service | 614 | $20,937 |
| OBSTETRICAL CARE | 29 | $10,263 |
| Short return visit (20+ min) | 74 | $7,456 |
| Fetal biophysical profile; without non-stress testing | 16 | $1,517 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 47 | $1,279 |
| FETAL NON-STRESS TEST | 204 | $1,126 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 19 | $672 |
| Service | 49 | $591 |
| URINE BACTERIA CULTURE | 41 | $286 |
| Service | 15 | $181 |
Drugs they prescribed that Part D paid
$15,684
Pharmacies billed $15,684 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
92 generic and fewer than 11 brand-name prescriptions · $15,684 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol (Twice Weekly) | 16 | $1,689 | $106 |
| Estradiol | 25 | $1,294 | $52 |
| Progesterone | 12 | $167 | $14 |
Year by year
| 2024 | 131 | 32 | None | None | $15,684 |
| 2023 | 160 | 38 | 0% (0) | 33% | $27,578 |
| 2022 | 145 | 32 | None | 37% | $29,032 |
| 2021 | 114 | 27 | 0% (0) | 35% | $18,153 |
| 2020 | 86 | 27 | None | 33% | $16,454 |
| 2019 | 88 | 32 | None | 31% | $13,890 |
| 2018 | 57 | 22 | None | 42% | $7,769 |
| 2017 | 80 | 25 | None | 34% | $7,830 |
| 2016 | 116 | 32 | None | 35% | $10,514 |
| 2015 | 106 | 24 | None | None | $8,148 |
| 2014 | 189 | 23 | None | 50% | $18,276 |
| 2013 | 196 | 23 | None | 52% | $16,081 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Estradiol (Twice Weekly) | 24 | $2,435 | $101 |
| Estradiol | 26 | $2,423 | $93 |
| Vagifem | 11 | $2,008 | $183 |
| Progesterone | 15 | $295 | $20 |
2022: 2 drugs
| Vagifem | 13 | $2,374 | $183 |
| Estradiol | 26 | $1,943 | $75 |
2021: 2 drugs
| Estradiol | 22 | $2,795 | $127 |
| Vagifem | 13 | $2,374 | $183 |
2020: 2 drugs
| Estradiol | 27 | $4,569 | $169 |
| Vagifem | 12 | $2,170 | $181 |
2019: 2 drugs
| Estradiol | 30 | $4,928 | $164 |
| Vagifem | 12 | $2,192 | $183 |
2018: 2 drugs
| Estradiol | 15 | $2,487 | $166 |
| Vagifem | 13 | $2,375 | $183 |
2017: 1 drug
| Vagifem | 13 | $2,200 | $169 |
2016: 3 drugs
| Vagifem | 15 | $2,768 | $185 |
| Evista | 12 | $2,353 | $196 |
| Hydrochlorothiazide | 12 | $33 | $3 |
2015: 2 drugs
| Evista | 11 | $2,217 | $202 |
| Hydrochlorothiazide | 12 | $42 | $4 |
2014: 3 drugs
| Combipatch | 32 | $2,700 | $84 |
| Vivelle-Dot | 30 | $2,568 | $86 |
| Prefera-Ob Plus Dha | 13 | $882 | $68 |
2013: 5 drugs
| Vivelle-Dot | 32 | $2,376 | $74 |
| Climara | 12 | $1,962 | $164 |
| Combipatch | 25 | $1,826 | $73 |
| Prefera-Ob Plus Dha | 13 | $838 | $64 |
| Estradiol | 16 | $134 | $8 |
Money from drug and device companies
$62 in 2025
| 2025 | 3 | 3 | None | $62 |
| 2024 | 1 | 2 | None | $45 |
| 2023 | 8 | 15 | None | $435 |
| 2022 | 5 | 25 | None | $630 |
| 2021 | 8 | 58 | None | $1,149 |
| 2020 | 4 | 21 | None | $893 |
| 2019 | 8 | 18 | None | $720 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Myfembree | $22 | 1 payment
|
| Lilly USA | Mounjaro | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Lynkuet | $20 | 1 payment
|
See all 3 published payments
| Sumitomo Pharma America | Meals · 2025-11-24 | Myfembree | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-18 | Lynkuet | $20 |
| Lilly USA | Meals · 2025-08-04 | Mounjaro | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $45
| Pfizer | Myfembree | $45 | 2 payments
|
2023: $435
| Abbvie | Lo Loestrin Fe | $183 | 7 payments
|
| Organon | None | $125 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $40 | 2 payments
|
| Pfizer | Myfembree | $20 | 1 payment
|
| Merck Sharp & Dohme | Gardasil 9 | $19 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $18 | 1 payment
|
| Mycovia Pharmaceuticals | Vivjoa | $17 | 1 payment
|
| Mayne Pharma Commercial | None | $13 | 1 payment
|
2022: $630
| Abbvie | Lo Loestrin Fe | $369 | 14 payments
|
| Myovant Sciences | Myfembree | $178 | 6 payments
|
| Evofem Biosciences | Phexxi | $35 | 2 payments
|
| TherapeuticsMD | Annovera | $33 | 2 payments
|
| Shield Therapeutics | Accrufer | $15 | 1 payment
|
2021: $1,149
| AbbVie | Orilissa | $815 | 36 payments
|
| Evofem Biosciences | Phexxi | $121 | 10 payments
|
| TherapeuticsMD | Annovera | $74 | 5 payments
|
| Mayne Pharma | None | $47 | 2 payments
|
| Myovant Sciences | Myfembree | $38 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $21 | 1 payment
|
| Hologic | Acessa Provu System | $21 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $12 | 1 payment
|
2020: $893
| Olympus Corporation of the Americas | Thunderbeat | $615 | 9 payments
|
| AbbVie | Oriahnn | $248 | 10 payments
|
| Evofem Biosciences | Phexxi | $16 | 1 payment
|
| Allergan | Lo Loestrin Fe | $14 | 1 payment
|
2019: $720
| Olympus Corporation of the Americas | Thunderbeat | $387 | 4 payments
|
| AbbVie | Orilissa | $191 | 6 payments
|
| Allergan | Botox | $40 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $33 | 1 payment
|
| ASCEND Therapeutics US | Estrogel | $22 | 2 payments
|
| Roche Diagnostics | Rs Harmony Test Related Products | $18 | 1 payment
|
| CooperSurgical | Endosee | $15 | 1 payment
|
| Exeltis USA | Slynd | $15 | 1 payment
|
Professional record
- NPI
- 1861484420
- Licence
- CA A82969California A82969: Current · expires 2026-10-31
- Trained
- University of Michigan Medical School, 2001
- Group
- Obhg California PC
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 800 Fairmount Ave, Suite 410a, Pasadena, CA, 91105
- NPI first listed
- 2005-08-19
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.